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Abstract
BACKGROUND: Survival rates for children with cancer have significantly increased over the 
past 35 years. However, adolescents with cancer aged 15 to 19 years have had less progress in 
survival prolongation compared with younger children, which may be due to lower clinical trial 
enrollment among adolescents with cancer. To help address this issue, the Centers for Disease 
Control and Prevention (CDC) convened a series of webinars to identify salient issues and 
measures to address this problem. This supplement is intended to raise awareness about the unique 
challenges of clinical trial enrollment among adolescents with cancer.
METHODS: The CDC convened a workgroup of researchers and health care providers in the field 
of adolescent and young adult oncology and cancer survivorship to examine the barriers and 
challenges limiting the participation of adolescents in clinical trials and to define ways to improve 
on these concerns.
RESULTS: The workgroup identified 3 distinct issues affecting clinical trial enrollment among 
adolescents with cancer: (1) many adolescents with cancer are not referred to institutions where 
clinical trials are offered, (2) there are limited numbers of clinical trials for adolescents with 
cancer, and (3) psychosocial barriers impede adolescents with cancer from enrolling in clinical 
trials.
CONCLUSIONS: Adolescents with cancer have the smallest proportion and least number of 
patients enrolled in clinical trials in pediatric oncology. Successfully addressing this challenge 
requires improving referral to existing clinical trials, addressing regulatory barriers to clinical trial 
enrollment, increasing the number of clinical trials for adolescents, and addressing unique 
psychosocial barriers to clinical trial enrollment. Pediatrics 2014;133:S85—S90
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The increasing survival of children with cancer has been one of the greatest success stories 
in the practice of medicine during the past half century. Childhood cancer mortality has 
decreased by >50% from 1975 to 2006.1,2 Much of this substantial improvement in survival 
is directly attributable to increasing enrollment of children with cancer in clinical trials.2–5 
Clinical trials allow more effective therapeutic treatments to be identified and provided to 
patients with cancer. For many decades, national clinical trials designed for children were 
primarily focused on children <15 years of age.6 Indeed, the first national clinical trials in 
the United States were conducted in the mid-1950s in young children with acute 
lymphoblastic leukemia and Wilms tumor who were predominantly <5 years of age. The 
focus on younger children has resulted in a lack of clinical trials for older adolescents aged 
15 to 19 years of age. The proportion of patients with cancer enrolled in a National Cancer 
Institute (NCI)-sponsored treatment trial has been shown to decrease with age (Fig 1).7 
Although the majority of children under the age of 15 years are enrolled in clinical trials, 
<20% of adolescents aged 15 to 19 years are enrolled in clinical trials.3–5,7–10 This situation 
has led to gaps in survival rates between adolescents and younger children for many types of 
cancer (Fig 2). Across most pediatrictype cancers, children >15 years of age have had less 
progress in survival prolongation compared with children <15 years of age.11–14 Figure 3 
displays the annual observed survival of all invasive cancers in 15- to 19-year-olds and 0- to 
14-year-olds from 1975 to 2004. Survival among 15- to 19-year-olds was relatively constant 
from 1986 to 2002, during which children <15 years of age continued to have improved 
survival and, by the early 1990s, caught up with 15- to 19-year-olds. Since 2000, 15- to 19-
year-olds have had some improvement in overall survival such that both age groups have had 
similar survival prolongation. The lack of clinical trial enrollment among adolescents with 
cancer undoubtedly has played a central role in the lack of improved survival in this 
population. One reason adolescents with cancer are not enrolled in clinical trials is the 
treatment setting in which they receive care. Adolescents suspected of cancer are referred by 
primary care physicians to either pediatric or adult oncologists. However, there is increasing 
evidence that adolescents treated by pediatric oncologists and at NCI-sponsored cancer 
centers are more likely to be enrolled in a clinical trial. Despite this finding, more 
adolescents are treated by adult oncologists and referrals to adult oncologists increase with 
the increasing age of adolescents.15–18 This is shown in Fig 4: with every year of age above 
14, the proportion of newly diagnosed patients with cancer referred to the only children’s 
hospital in the region declined an average of 14% per year, from 85% in 14 year-olds to <5% 
in 21-year-olds. A small proportion of the age group was referred to the comprehensive 
cancer center at the region’s academic medical center. The majority remained in private 
practice, with approximately one-third of these at practices not certified by the American 
College of Surgeons. Because the treatment setting in which adolescents are referred to 
receive their cancer workup and treatment is so critical, pediatricians play a key role in 
shaping the long-term outcomes of adolescents with cancer.
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The Carolyn Price Walker Act of 2008 authorized federal agencies to expand and enhance 
research, surveillance, and awareness activities related to pediatric cancer, including 
improving access to clinical trials for children with cancer.19 To ensure that adolescents 
shared in the improvements in cancer survival seen among younger children, the CDC 
initiated a project to identify the salient issues and measures to address this problem. We 
first performed a literature review of the available evidence on this topic. Next, we convened 
an informal workgroup of leading pediatric and adult oncologists, behavioral scientists, 
nurses, and researchers from academia and government (Table 1). We then held a series of 3 
webinars with the workgroup to define barriers to clinical trial enrollment and to provide 
recommendations on addressing them. This monograph, which includes a series of articles, 
is intended to raise awareness among pediatricians, the predominant type of primary care 
physician caring for adolescents, about the unique challenges of clinical trial enrollment 
among adolescents with cancer.
RESULTS
On the basis of 3 workgroup webinars, 3 distinct issues were identified that may explain 
why adolescents with cancer in the United States have not fared as well as the younger 
pediatric population:
1. many adolescents with cancer are not referred to NCI-sponsored institutions 
where clinical trials are offered;
2. there are limited numbers of clinical trials for adolescents with cancer and 
increasing their availability is difficult; and
3. psychosocial barriers impede adolescents from enrolling in clinical trials.
Webinar 1: “Potential Barriers to Clinical Trial Enrollment Among Adolescent Cancer 
Patients”
Daniel Indelicato and Archie Bleyer reported the lack of available clinical trials for 
adolescents. This was illustrated by lymphoma clinical trials among adolescents. Although 
the incidence of lymphoma is relatively high among adolescent patients compared with other 
pediatric cancers, there are limited available treatment clinical trials for these patients.20 
This situation was also revealed by the University of Pittsburgh Medical Center Cancer 
Center’s (UPMC-ML’s) and Children’s Hospital of Pittsburgh’s (CHP’s) experience. At 
UPMC and CHP, the rate of adolescents enrolled in clinical trials was lower than that of the 
younger pediatric population and may have been due to the lack of available trials at the time 
of their diagnosis.10
Simply increasing the number of clinical trials for adolescents and young adults (AYAs) is 
not feasible, as pointed out by Abha Gupta and Daniel Indelicato in this monograph series. 
As a member of the Children’s Oncology Group Soft Tissue Sarcoma Steering Committee, 
Gupta recognizes that it is challenging to design clinical trials when survival rates are 
already high in some diseases, but continued efforts are needed in incorporating AYA-
specific aims into cooperative group trials. Although collaboration between pediatric and 
adult oncology cooperative groups is ideal, the complexities of regulatory barriers may 
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overshadow the pursuit of such partnerships as shown by Judy Felgenhauer, Vice-Chair of 
the Children’s Oncology Group AYA Steering Committee.
Webinar 2: “Where Are Adolescent Cancer Patients Being Treated and What’s Going on in 
Their Heads?”
This session focused on the regulatory barriers that exist across different hospital settings 
and among pediatric and adult hospitals. Adolescents with cancer are often not treated at 
centers where clinical trials are offered, or if they are, these trials often have an age cutoff to 
include only those who are >18 years old. Pediatric and adult hospitals, sometimes within 
the same institution, may have separate in stitutional review boards, hindering enrollment in 
clinical trials that encompass both adolescents and young adults. The lack of use of a central 
institutional review board also limits the enrollment of adolescents from different institutions 
within a study. Unfortunately, there is no easy solution for such instances, and Felgenhauer 
et al outline some regulatory issues through different patient scenarios.
Despite regulatory issues and a decline in the number of clinical trials available for 
adolescents, data indicate that even within institutions treating children and adolescents, the 
latter group has decreased accrual rates onto clinical trials. There seems to be some promise 
in dedicated AYA programs that many cancer centers have established to help address this 
issue. At UPMC, it was noted that more AYAs are being treated at UPMC-ML, but those 
treated at CFIP had a higher enrollment rate in clinical trials.21,22 Since the establishment of 
the AYA program at UPMC, there has been an increase in the number of young adults 15 to 
22 years of age enrolled in a clinical trial. In this monograph, Peter Shaw, head of the AYA 
program at UPMC, focuses on how to increase the opportunities for adolescents to enroll in 
studies.
A significant feature of both webinars 1 and 2 was the psychosocial aspect of adolescents. A 
large part of AYA oncology rests on the recognition that AYAs have psychosocial issues 
unique to this population. Studies have shown that AYAs with cancer have more distress 
associated with a cancer diagnosis23,24 compared with younger patients, and adolescent 
cancer survivors report having a worse quality of life than both survivors of childhood 
cancer25 or their age-matched healthy peers.26 Flow this affects treatment decisions is 
unclear, more so when considering whether psychosocial challenges affect AYAs in 
enrolling in clinical trials. The AYA Health Outcomes and Patient Experience is a 
population-based cohort study in AYAs with cancer that is supported by the NCI. This 
longitudinal study included patients with cancer who were 15 to 39 years of age diagnosed 
between July 2007 and October 2008 and includes addressing clinical trial involvement 
among AYA patients27 The psychosocial barriers to clinical trial enrollment and adherence 
are further discussed by Natasha Buchanan in this monograph.
A major clinical trial enrollment barrier identified through the webinarswas the decreased 
number of referrals of AYAs with cancer to an NCI-sponsored institution. Adolescents are 
often treated at community hospitals and private oncology practices.16,17 The drop-off in 
referral rates to a children’s hospital among adolescents over the age of 15 years of age is 
dramatic and helps explain the decline in enrollment in NCI-sponsored trials. Across most 
pediatric types of cancers, children >15 years of age generally have lower overall survival 
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rates compared with children <15 years. Karen Albritton and Peter Coccia address this topic 
in this monograph and provide recommendations on how referral rates can improve.
Webinar 3: Summary
On the basis of discussion from the first 2 webinars, webinar 3, led by workgroup chair 
Archie Bleyer, focused on identifying key barriers to clinical trial enrollment. One key 
barrier was that adolescents are not referred to institutions at which clinical trials are offered. 
A second barrier is the limited number of clinical trials available for adolescents with cancer. 
Even if adolescents are referred to appropriate treatment settings, there may not be a trial 
available for those patients and increasing the number of trials is difficult. Psychosocial 
barriers are a third key obstacle to increasing adolescent enrollment in clinical trials. 
Addressing these barriers will require increased awareness of these issues among referring 
physicians, closer collaboration between physicians, and increased research efforts. Efforts 
to increase awareness about survival trends, empower adolescents and famiIies about 
treatment choices, and support local efforts focused on AYA cancers are also needed.
CONCLUSIONS
This project revealed that, across all pediatric cancers, adolescents 15 to 19 years of age 
have poorer outcomes compared with younger patients across disease types and have the 
smallest proportion and least number of patients enrolled in clinical trials in pediatric 
oncology.
Since these webinars were held, in 2012, changes are starting to be implemented. As 
mentioned in Gupta and Indelicato’s report in this monograph, the NCI has introduced a 
comprehensive plan to transform the previous NCI-sponsored Clinical Trials Cooperative 
Group Program, which funded several separate organizations conducting cancer treatment 
trials, into a new consolidated and integrated program referred to as the NCI National 
Clinical Trials Network. This new program will allow access to clinical trials offered by a 
number of cooperative oncology groups regardless of which group the treating oncologist 
may be a member of.
In 2012, the National Comprehensive Cancer Network (NCCN) published the first-ever AYA 
clinical practice guidelines.28 The NCCN is a not-for-profit alliance of 21 leading cancer 
centers dedicated to improving the quality and effectiveness of care provided to patients with 
cancer. The establishment of the NCCN AYA guidelines is instrumental in increasing the 
awareness among oncologists about AYA cancers and may have an impact on referral 
patterns of AYA patients.
The barriers identified through this series of webinars are straightforward yet challenging. 
Successfully addressing these challenges will require improving referral to existing clinical 
trials, addressing regulatory barriers to clinical trial enrollment, increasing the number of 
clinical trials for adolescents, and addressing the unique psychosocial barriers to clinical trial 
enrollment and adherence for adolescents with cancer. Primary care physicians, and in 
particular pediatricians, play a key role in addressing these challenges. Closer engagement 
between pediatriciansandthepediatricandadult oncology communities is needed to ensure 
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that adolescents with cancer are referred to physicians and treatment centers that provide 
access to clinical trials. Collaboration between pediatricians and oncologists is also needed 
for the long-term well-being of adolescents with cancer.
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FIGURE 1. 
Estimated proportion of patients with cancer entered in NCI-sponsored treatment trials, 
1997–2005. The black bar represents patients age 15–19 years with cancer entered in NCI-
sponsored treatment trials. Clinical trials accrual data were provided by the Cancer Therapy 
Evaluation Program, NCI. Population data were obtained from the US Census Bureau.7
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FIGURE 2. 
Gap in survival rates for selected cancers in 15- to 19-year-olds versus those in < 15-year-
olds.14
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FIGURE 3. 
Annual 5-year observed survival for all invasive cancers, 1975–2004: Surveillance, 
Epidemiology, and End Results.
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FIGURE 4. 
Referral patterns of patients with newly diagnosed cancer before age 25, by age, to the state 
children’s hospital and the state university adult center. Modified from reference 16.
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